Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Recruiting 2Suspended 1Completed 1

Sponsor Class

OTHER 4NIH 3NETWORK 3

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Carcinoma, Non-Small-Cell Lung 11Squamous Cell Carcinoma of Head and Neck 8Oropharyngeal Neoplasms 7Cholangiocarcinoma 7Pancreatic Neoplasms 6Lung Neoplasms 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Mouth Neoplasms 4Laryngeal Neoplasms 4Gallbladder Neoplasms 4Carcinoma 4Sarcoma 3Hypopharyngeal Neoplasms 3Fallopian Tube Neoplasms 3Urethral Neoplasms 2Stomach Neoplasms 2Peritoneal Neoplasms 2Paranasal Sinus Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Klatskin Tumor 2Colorectal Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Stomatitis 1

Interventions

Cisplatin 21pembrolizumab 16Gemcitabine 16Paclitaxel 15Radiotherapy 14Carboplatin 14Radiotherapy, Intensity-Modulated 13Cyclophosphamide 9Cetuximab 9Magnetic Resonance Spectroscopy 8Radiation 7padeliporfin 6Specimen Handling 6Oxaliplatin 6Fluorouracil 6Drug Therapy 6Docetaxel 6Capecitabine 6Bevacizumab 6anlotinib 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Celecoxib 5poly ICLC 4fludarabine 4Standard of Care 4Sorafenib 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT05541016 2026-05-12

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Mayo Clinic

Phase 2 Recruiting
455 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology

Phase 2/3 Suspended
1,714 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NRG Oncology

Phase 2 Recruiting
98 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT04541355 2024-06-28

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

University of California, San Francisco

Phase 2 Completed
16 enrolled 12 charts
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡